Associate Director, Nonclinical Development

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases.

The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects.

Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF).

AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone.

Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF).

Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform.

By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies.

For more information, please visit avalynpharma.com and follow the company on LinkedIn .

The Associate Director, Nonclinical Development will serve as a key scientific contributor within the Translational Sciences organization, supporting the advancement of Avalyn's pipeline through pre-clinical and clinical development stages.

This individual will contribute to integrated development strategies that leverage pharmacology, translational science, biomarkers, and nonclinical evidence packages to inform candidate progression, dose selection, regulatory submissions, and clinical development plans.

Reporting to the VP, Translational Sciences, the role requires strong pharmacology expertise, excellent scientific judgment, and exceptional technical writing skills to effectively synthesize and communicate complex data to cross-functional teams, regulatory agencies, and external stakeholders.